We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Saturday
May 03
09:00 - 10:00
Business 1-2
Sarcoma / Skin cancer / Malignant melanoma
Bruno Fionda, Italy;
Clare David, United Kingdom
Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will be recorded and made available via the online platform and mobile app.
Mini-Orals
Clinical
FLASH / Skin / Soft Tissue
09:00 - 09:07
Prognostic subgroups for disease-free survival in cutaneous squamous cell carcinoma of the head and neck: A secondary analysis of the TROG 05.01 Trial
Emma Connolly, Australia
E25-1045
09:07 - 09:14
A first analysis of a phase 1 dose escalation trial of FLASH radiotherapy in patients with skin metastases from melanoma- (NCT04986696)
Rémy Kinj, Switzerland
E25-1119
09:14 - 09:21
Cosmetic outcome and patient satisfaction after radiotherapy of Squamous Cell Carcinomas (SCC) of the skin - a multi-institutional prospective study
Jesper Grau Eriksen, Denmark
E25-4089
09:21 - 09:28
A Retrospective Outcome Study for Proton Beam Therapy in Ewing's Sarcoma: The First UK experience.
Shweta Sharma, United Kingdom
E25-2574
09:28 - 09:35
Proton therapy in patients with thoracic Ewing sarcomas; Early Result from the Prospective Registry Studies KiProReg and ProReg
Beate Timmermann, Germany
E25-2433
09:35 - 09:42
949-patient database of Merkel cell carcinoma of the skin: the optimal nodal radiotherapy volume
Kurian Joseph, Canada
E25-3108
09:42 - 09:49
Efficacy of Radiotherapy and Radiotherapy with Hyperthermia to prolong systemic therapy for patients with metastatic melanoma oligoprogerssion
Aneta Borkowska, Poland
E25-2977
09:49 - 09:56
Preliminary dose-volume constraints predicting subcutaneous tissue fibrosis for limb sarcoma using the VorteX and IMRiS trials.
Rita Simoes, United Kingdom
E25-3942